Drug intelligence / Profile preview

iHSC014

Development stage: Preclinical
Lead developer: Cell Inspire Biotechnology
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

iHSC014 is an induced pluripotent stem cell (iPSC)-derived hematopoietic stem cell (HSC) therapy developed by Cell Inspire Biotechnology. The therapy utilizes the company's proprietary HIP01 hypoimmune engineering platform, which is designed to reduce the immune recognition and rejection of the transplanted cells by the recipient's immune system. By creating a hypoimmune cell product, iHSC014 aims to provide a universal, off-the-shelf source of hematopoietic stem cells, potentially eliminating the need for donor-recipient HLA matching in the treatment of various hematological disorders and other conditions requiring stem cell transplantation. The product is currently in the preclinical stage of development.

Beyond the preview

Go deeper on iHSC014.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iHSC014.

Explore the full profile